Skip to content
ClinCalc Pro
Menu
Vestibular Suppressant — Vertigo

Cinnarizine

Brand names: Stugeron

Cinnarizine is an antihistamine with vestibular-sedative properties used for vertigo and the symptoms of Ménière's disease, and for the prevention and treatment of motion sickness.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It is an H1-antihistamine that also has calcium-channel-blocking activity in the vestibular system, damping the response to vestibular stimulation; central antihistaminic and antidopaminergic actions contribute to both its antiemetic effect and its adverse effects.

Prescribing in practice

  • It can cause or worsen extrapyramidal symptoms and parkinsonism, particularly in older people, so avoid prolonged use in the elderly and review for new movement disorders.
  • It commonly causes drowsiness, which is additive with alcohol and other sedatives and may impair driving and skilled tasks.
  • Anticholinergic effects (such as dry mouth, blurred vision and urinary hesitancy) can occur; use caution where these would be hazardous.

Monitoring

No routine laboratory monitoring is required; on continued use, review for excessive sedation and for parkinsonian or other extrapyramidal features, especially in older patients.

Counselling the patient

  • It can make you drowsy — avoid alcohol and do not drive or operate machinery until you know how it affects you.
  • For motion sickness, take it before travelling.
  • Report any tremor, stiffness, slowness of movement or restlessness, particularly with longer-term use.

Evidence & guidelines

An established option for vestibular symptoms and motion sickness; in older people the risk of drug-induced parkinsonism favours short-term use and alternatives where possible.

Reference: BSO Menière's Disease Guidelines; NICE CKS Vertigo; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.